Form 4: Enanta Pharmaceuticals CFO Sells Shares to Cover Tax Obligations

Enanta Pharmaceuticals' Chief Financial and Administrative Officer, Paul J. Mellett, sold 2,591 shares of common stock to cover tax obligations related to a restricted stock unit award.

Summary

• Paul J. Mellett, the Chief Financial and Administrative Officer of Enanta Pharmaceuticals, Inc., sold 2,591 shares of common stock on December 6, 2024.
• The sale was executed to cover withholding taxes due from the settlement of a restricted stock unit award granted on November 23, 2022.
• The shares were sold at a weighted-average price of $8.06, with individual transactions ranging from $7.87 to $8.22.
• Following the transaction, Mr. Mellett directly owns 91,710 shares of Enanta Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment towards the company's performance.

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.

Comparison to Industry Standards

• Similar transactions are common among executives at publicly traded companies, particularly in the biotechnology sector where stock-based compensation is a significant part of executive pay.
• Companies like Gilead Sciences, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals also see similar Form 4 filings from their executives regularly.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Enanta Pharmaceuticals, Paul J. Mellett, stock sale, Form 4, insider trading, restricted stock unit, tax obligations